Brioli, Annamaria http://orcid.org/0000-0002-4072-7592
Gengenbach, Laura
Mancuso, Katia http://orcid.org/0000-0002-1169-0129
Binder, Mascha http://orcid.org/0000-0003-0663-3004
Ernst, Thomas http://orcid.org/0000-0003-2147-489X
Heidel, Florian H. http://orcid.org/0000-0003-2438-1955
Stauch, Thomas
Zamagni, Elena http://orcid.org/0000-0003-1422-7305
Hilgendorf, Inken http://orcid.org/0000-0003-2038-9730
Hochhaus, Andreas http://orcid.org/0000-0003-0626-0834
Engelhardt, Monika http://orcid.org/0000-0003-0405-1676
von Lilienfeld-Toal, Marie
Funding for this research was provided by:
Universitätsmedizin Greifswald
Article History
Received: 3 January 2023
Accepted: 5 February 2023
First Online: 13 February 2023
Declarations
:
: AB has participated in advisory boards from BMS/Celgene, Janssen, GSK, Takeda, and Sanofi and received honoraria and travel support from BMS/Celgene, Janssen, GSK, Sanofi, AMGEN, Gilead, and Takeda; KM has received honoraria from BMS/Celgene, Janssen, Amgen, Takeda, Pfizer, GSK, and Sanofi; MB has received honoraria from BMS/Celgene; FHH has received research funding from BMS/Celgene and served as an advisor for BMS/Celgene and Janssen; TS has participated in advisory boards from Novartis, has received honoraria from Novartis, Amgen, Alexion, Janssen, AOP, BMS, Grifols and has received research support from Novartis, Amgen, Sobi, Argenx, and Grifols; EZ has received honoraria and is an advisory board member for BMS/Celgene, Janssen, Amgen, Sanofi, GSK; AH received research support by Novartis, BMS/Celgene, Pfizer, and Incyte; MvLT has received honoraria from Celgene, Gilead, Chugai, Janssen, Novartis, Amgen, Takeda, BMS, Medac, Oncopeptides, Merk, CDDF, AbbVie, AstraZeneca, Pfizer, Thermofisher, GSK, and Shionogi and research funding from BMBF, Deutsch José Carreras Leukämie-Stiftung, IZKF Jena, DFG, Novartis, Gilead, Deutsche Krebshilfe, BMS/Celgene, Oncopeptides. All the other authors have no conflicts of interest to declare.